A genome-wide association study in human lymphoblastoid cells supports safety of mitochondrial complex I inhibitor.

Abstract excerpt

Novel therapeutic strategies for Alzheimer's disease (AD) are of the greatest priority given the consistent failure of recent clinical trials focused on Aβ or pTau. Earlier, we demonstrated that mild mitochondrial complex I inhibitor CP2 blocks neurodegeneration and cognitive decline in multiple mouse models of AD. To evaluate the safety of CP2 in humans, we performed a genome-wide association study (GWAS) using...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Electron Transport Complex I
• Share to Enzyme Inhibitors